Latest stories on MRKR
Marker Therapeutics awarded $2.6M FDA Orphan Products development grant
The Fly64 · neutralproduct/pr
Marker Therapeutics, Inc. (MRKR) files 8-K
SEC 8-K50 · neutralgeneral
Marker Therapeutics Awarded $2.6 Million FDA Orphan Products Development Grant to Advance MT-601 in Pancreatic Cancer
GlobeNewswire64 · neutralproduct/pr
Marker Therapeutics Highlights Expanded Manufacturing Support of CDMO Partner Following Formation of Kincellis Advanced Therapies
GlobeNewswire63 · neutralproduct/pr
H.C. Wainwright reiterates Marker Therapeutics stock rating at buy
Investing.com Analyst Ratings61 · neutralanalyst
Labcorp Launches Marker by Labcorp™ Genetic Health Panel, Expanding Consumer Access to Hereditary Genetic Risk Testing
PR Newswire63 · neutralproduct/pr
Mile Marker Acquires LIFT to Advance Content Marketing Capabilities
PR Newswire62 · neutralm&a